Prudential PLC Raises Stake in Amgen Inc. (NASDAQ:AMGN)

Prudential PLC raised its position in Amgen Inc. (NASDAQ:AMGNGet Rating) by 33.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,509 shares of the medical research company’s stock after acquiring an additional 12,512 shares during the quarter. Prudential PLC’s holdings in Amgen were worth $11,138,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in Amgen in the fourth quarter worth approximately $26,000. Norwood Financial Corp acquired a new stake in Amgen during the fourth quarter worth approximately $28,000. Industrial Alliance Investment Management Inc. acquired a new stake in Amgen during the fourth quarter worth approximately $31,000. Econ Financial Services Corp acquired a new stake in Amgen during the fourth quarter worth approximately $34,000. Finally, PYA Waltman Capital LLC acquired a new stake in Amgen during the fourth quarter worth approximately $34,000. Institutional investors own 79.01% of the company’s stock.

A number of analysts have weighed in on the stock. Mizuho raised their price objective on shares of Amgen from $202.00 to $208.00 in a report on Tuesday, May 10th. Wells Fargo & Company lifted their target price on shares of Amgen from $210.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 9th. TheStreet cut shares of Amgen from a “b+” rating to a “c+” rating in a research note on Wednesday, April 27th. BMO Capital Markets dropped their price objective on shares of Amgen from $263.00 to $243.00 in a research note on Thursday, April 28th. Finally, Morgan Stanley dropped their price objective on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $240.40.

In other Amgen news, EVP Jonathan P. Graham sold 13,500 shares of the company’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the transaction, the executive vice president now directly owns 37,333 shares in the company, valued at approximately $9,027,492.73. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Shares of Amgen stock traded up $1.25 on Tuesday, hitting $245.12. The company’s stock had a trading volume of 106,026 shares, compared to its average volume of 3,365,221. Amgen Inc. has a 52-week low of $198.64 and a 52-week high of $258.45. The company has a quick ratio of 1.09, a current ratio of 1.44 and a debt-to-equity ratio of 39.31. The firm has a fifty day moving average price of $241.94 and a 200-day moving average price of $227.93. The company has a market capitalization of $130.94 billion, a P/E ratio of 24.03, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58.

Amgen (NASDAQ:AMGNGet Rating) last released its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, topping the consensus estimate of $4.22 by $0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The business had revenue of $6.24 billion for the quarter, compared to analyst estimates of $6.09 billion. During the same period in the previous year, the firm earned $3.70 EPS. As a group, analysts expect that Amgen Inc. will post 17.49 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Shareholders of record on Tuesday, May 17th will be issued a $1.94 dividend. The ex-dividend date is Monday, May 16th. This represents a $7.76 dividend on an annualized basis and a yield of 3.17%. Amgen’s dividend payout ratio (DPR) is 76.38%.

About Amgen (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.